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Abstract
The failure of the cellular immune response to stop solid
tumor growth has been the subject of much research.
Although the mechanisms for tumor evasion of immune
response are poorly understood, one viable explanation
is that tumor-killing lymphocytes cannot reach the
tumor cells in sufficient quantity to keep the tumor in
check. Recently, the use of bifunctional antibodies
(BFAs) has been proposed as a way to direct immune
cells to the tumor: one arm of the antibody is specific for
a known tumor-associated antigen and the other for a
lymphocyte marker such as CD3. Injecting this BFA
should presumably result in cross- linking of lympho-
cytes (either endogenous or adoptively transferred)
with tumor cells, thereby enhancing therapy. Results
from such an approach, however, are often disappoint-
ing — frequently there is no benefit gained by using the
BFA. We have analyzed the retargeting of endogenous
effector cells by BFA using a physiologically based
whole-body pharmacokinetic model that accounts for
interactions between all relevant species in the various
organs and tumor. Our results suggest that the design
of the BFA is critical and the binding constants of the
antigen and lymphocyte binding epitopes need to be
optimized for successful therapy.
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Introduction
Adoptive effector cell therapy relies on the delivery of
lymphokine-activated and expanded effector cells or specific
tumor- infiltrating lymphocytes and activated natural killer
cells. Administration of interleukin-2–activated effector cells
has been shown to create significant clinical toxicity [1,2 ],
and the isolation of specific lymphocytes that target tumor
tissues is difficult and only possible when antigens have
been isolated from the specific tumor cell line. For clinical
application, an ideal immunotherapy would direct the
body’s endogenous effector cells to a tumor and only
activates the effector cells in the presence of tumor
antigens. Such therapies are being explored using bifunc-
tional antibodies (BFAs) that have specificity for both a
tumor antigen and the T-cell receptor–CD3 complex on T
cells [3–14]. These BFAs have been engineered with the
expectation that they will induce the T-cell repertoire to
generate lytic and inflammatory responses at the tumor site.
F(ab0 )2 BFAs, which lack functional Fc portions, have been
shown to induce lymphocyte proliferation only in the presence
of tumor cells and produce no in vivo systemic activation
[8,15]. The availability of many antitumor antibodies, includ-
ing several that demonstrate broad antitumor reactivity
against a variety of human adenocarcinoma cell lines, and
the ability of F(ab0 )2 antibodies to penetrate tumors more
efficiently than full -size antibodies has generated consider-
able interest in this form of therapy [3–5,10].
The application of retargeting endogenous effector cells
using BFAs will require the optimization of several BFA
properties and treatment conditions. The systematic eval-
uation of the effects of changing these variables is perfectly
suited to analysis using a physiologically based pharma-
cokinetic model. Such a model can be used to study BFA
and lymphocyte biodistribution by examining the signifi-
cance of transport mechanisms and BFA properties with
respect to the localization of effector cells at a tumor site.
The results from these modeling studies can be used to
more effectively guide preclinical experiments and bridge
the gap between the optimal preclinical conditions and
therapy in humans.
The objective of the research presented in this paper is to
develop a pharmacokinetic model that can be used in the
design of BFA-directed effector cell therapies. Two pre-
viously developed models that were used to individually study
the distribution of antibodies [16] and effector cells [17,18]
form the basis for this work. Both models are physiologically
based, using measurable physiological parameters such as
organ volumes and blood flow rates and incorporating the
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mechanism-based transport processes that determine how
antibodies and effector cells distribute in the body.
Data collected by Bakacs et al. [19] was used to
estimate unknown parameters for use in the model in the
absence of experimental values for these parameters.
Bakacs et al. followed the biodistribution of a BFA after IV
administration in a syngeneic mammary adenocarcinoma
BALB/c mouse model. A lung metastasis model and a
subcutaneous solid tumor model were considered. In the
former, 64PT cells were IV injected into the tail vein of
BALB/c mice. BFA treatment was found to prolong the
survival of these mice. In contrast, the BFA was unable to
prolong the survival of mice with subcutaneous 64PT tumor
grafts. A biodistribution study showed that the BFA was
accumulating preferentially in the spleen and lymph nodes,
as it was designed to bind to the T cells abundant in these
tissues, rather than in the subcutaneous tumor. The
authors suggested that poor vascularity or physiological
barriers presented by the solid tumors may have prevented
the BFA and T cells from infiltrating the tumor. Smaller
tumors, such as those in the lung metastases model, may
not present such barriers. Our research focuses on the
poor homing of BFA to solid tumors. Our model supports
the observations of Bakacs et al. and further examines how
the interplay between BFA, lymphocytes, and tumor
antigen may be exploited to optimize antibody-mediated
adoptive immunotherapy.
Methods
Model Development
The model we developed to study BFA distribution and
retargeting of lymphocytes is based on two previously
developed models. A whole-body physiologically based
model is used in which the major organs of the body are
represented as compartments that are connected in an
anatomical manner by the systemic and lymphatic circulation
(Figure 1). The organ compartments are then further
subdivided into vascular and extravascular subcompart-
ments. The detailed description of the antibody and effector
cell transport processes is adapted from previous models
[18,20,21]. Briefly, the main transport processes in the
antibody model include: convective and diffusive transport
across capillary walls; reversible, nonsaturable, nonspecific
binding in the extravascular compartments; reversible,
saturable, specific binding to tumor antigens; and elimination
through the kidneys. The main transport processes in the
effector cell model include: capture and arrest at the en-
dothelial wall through cell adhesion molecules; extravasation
of arrested lymphocytes into the extravascular compartment;
and depletion of cells through either a catabolic process or
apoptosis. In addition to these processes, the model
developed in the present study accounts for saturable
binding between BFAs and lymphocytes and the normal
production of endogenous lymphocytes. Functional, immu-
nohistochemical, and morphologic studies indicate that the
vascular endothelium of tumor vessels may be partially
composed of tumor cells exposed to the blood flow [22–24].
Therefore, the model also accounts for binding of BFA and
BFA–lymphocyte complexes to antigens in the vascular
space of the tumor compartment. Figure 2 shows a
schematic of the two subcompartments of the tumor com-
partment and the associated BFA, lymphocyte, and BFA–
lymphocyte complex species. The model nomenclature is
given in Appendix A and the mass balance and other model
equations can be found in Appendices B and C, respectively.
Model Parameters
To facilitate comparison between model predictions and
the experimental data collected by Bakacs et al. [19], the
physiological parameters for mice were used in the
simulations (see Appendix A). The plasma flow rates for
the tumor, muscle, and skin were determined experimen-
tally; other plasma flow rates were obtained from the
literature [25]. Lymphatic flow rates and interstitial fluid
recirculation rates (JR,i ) were determined by fitting model
predictions to experimental data [21]. Total organ volumes
were determined experimentally by weighing each organ
and assuming a density of 1 g ml1 except for the bone
where a density of 1.5 g ml1 was assumed. Vascular and
interstitial volumes of organs were calculated as percen-
tages of total organ volume as given in the literature
[21,26,27]. These physiological parameters are summar-
ized in Appendix A.1.
The BFA osmotic reflection coefficients (sS, sL) for small
and large pores have been determined previously to be 0.96
and 0.11, respectively [21] and the BFA permeability–
surface area products (PSS, PSL) have been determined to
have values of 2.3105 and 7.9106 ml min1 g1,
respectively [21]. The binding affinity of the BFA to antigen
has been determined by Bakacs et al. [19] to be 3.0106
M1. The reverse binding rate constant of BFA to antigen
has been determined to be approximately 1.0102 min1
[21], which results in a forward binding constant of 3.0107
ml mol1 min1. The binding affinity of BFA to CD3
molecules on lymphocytes was determined by Bakacs et
al. [19 ] to have a value of 1.0107 M1. The reverse binding
rate constant of BFA to CD3 is not known; therefore, as an
Figure 1. Whole -body pharmacokinetic model. All the major organs are
included in the model, and the various compartments are interconnected by
the blood (black arrows ) and lymphatic ( gray arrows ) systems.
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initial estimate, the value for the reverse binding rate
constant between BFA and antigen was used (1.0102
min1), which resulted in a forward binding constant of
1.0108 ml mol1 min1. The density of CD3 molecules on
lymphocytes was estimated to be 7.5104 molecules per
cell, and a tumor antigen density of 1.21011 mol ml1 was
used as reported in the literature [28]. Nonspecific binding of
the BFA in the extravascular space was assumed to be
negligible due to the absence of an Fc domain that normally
accounts for the majority of nonspecific binding. The final
parameter related to BFA distribution is the rate of
elimination in the kidneys; this parameter was determined
by fitting the model to the experimental data.
The extravasation of lymphocytes from the vascular to the
extravascular space of organs requires ( i ) contact and
adhesion of the lymphocytes with the endothelial walls (cell
capture), ( ii ) stable adhesion (cell spreading), and ( iii )
extravasation into the interstitium. The relevant model
parameters are the density of endothelial adhesion sites in
each organ, the binding affinity between the lymphocytes
and adhesion sites, and the migration rate of a bound
lymphocyte across the endothelium.
The transcapillary migration rate used in the simulations
was 2.9104 min1 as estimated previously [17]. The rate
of capture, release, and arrest is expected to vary between
organs. Zhu et al. [17] achieved varying rates by fixing the
adhesion site density in each organ and calculating a varying
capture and arrest rate constant for each organ by fitting
model predictions to experimental data. In the simulations for
this study the capture, release, and arrest rate constants
were assumed to be equal in all organs with values of
9.01017 ml mol1 min1, 200 min1, and 1103 min1,
respectively, which are the average values determined by
Zhu et al. for nonactivated T cells [17]. This assumption was
made as a first approximation due to a lack of experimental
organ specific values. However, this is a reasonable
assumption because capture and arrest rates are expected
to vary between organs primarily because of differences in
adhesion site densities, not differences in the rate constants.
Adhesion site densities were allowed to vary between organs
and were estimated by fitting model predictions to exper-
imental data.
The rate of lymphocyte recirculation in the extravascular
space through the lymphatic circulation was previously
determined by Zhu et al. [17] to have values of 0.018,
0.01, and 1.0 for the lymph node, tumor, and all other tissues,
respectively.
The lymphocyte depletion rate constant was set at
4.2103 min1 in the lungs and zero in other tissues as
determined by Zhu et al. [17 ]. The rate of lymphocyte
generation in the body was determined by fitting the model-
calculated steady-state concentration of lymphocytes in the
plasma to the known concentration in mice, 9.01018 mol
ml1 [29]. Appendix A.2 summarizes the kinetic parameters
used in the model simulations.
Model Simulations
A FORTRAN program that incorporated the ordinary
differential equation solver LSODE was written to perform
the simulations. The differential equations that describe the
mass balance of each species in each tissue and sub-
compartment are given in Appendix B.
As mentioned previously, the unknown parameters that
were estimated by fitting experimental data were the
elimination rate of BFA in the kidneys, the normal rate of
generation of lymphocytes needed to maintain a constant
level in the body, and the density of adhesion sites on the
vascular endothelium in different organs. Data collected by
Bakacs et al. [19 ] was used in the parameter-estimation
process. Bakacs et al. studied the distribution of BFA in
BALB/c mice bearing subcutaneous tumors. Mice were
given subcutaneous injections of 64PT cells, which express
high levels of MMTV gp52 envelope glycoprotein, 6 days
before BFA treatments. Radiolabeled BFA, with specificity
for gp52 and CD3, was given through tail vein injection, and
organ radioactivity was measured at various times after
injection to determine the BFA biodistribution. This data was
used in the estimation of the vascular adhesion site densities
and the elimination rate of BFA in the kidneys.
The first step in the model simulations was to determine
the generation rate of lymphocytes required to maintain the
known normal steady-state concentration of lymphocytes in
the blood in the absence of BFA. This was accomplished by
setting the adhesion site density in each tissue to an
estimated initial value and then determining the generation
rate of lymphocytes required to maintain the correct con-
centration of lymphocytes in the blood. The second step in
the simulations was to fit the organ concentrations of BFA
(as determined by Bakacs et al. ). Because BFAs are able to
bind to lymphocytes, the concentration of BFA in the tissues
is in part regulated by the concentration of lymphocytes in
each tissue, which is in turn controlled by the adhesion site
density in the vascular space of the tissue. Therefore, the
BFA concentrations calculated by the model were fit to the
experimental data of Bakacs et al. by varying the adhesion
site density in each tissue in addition to the elimination rate of
Figure 2. The various species considered in the model. Effector cells ( large
circles ) can be bound to BFA (
=
=
=
- -), which can bind to tumor antigen ( green
diamonds ) or CD3 (blue squares ). Antibody can also bind nonspecifically in
the interstitial space (small circles ).
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BFA in the kidneys. The fitted values of adhesion site density
were then substituted for the initial values used in the first
step to calculate steady-state levels of lymphocytes, and a
new lymphocyte-generation rate was calculated. This two-
step fitting process was repeated until the model produced
good fits using the same parameter values in both fitting
steps.
Nonlinear regression fitting routines were used to fit the
experimental data. Two different routines were used, and the
resulting parameters were compared as a check of con-
sistency. The two routines produced parameter values with
the same order of magnitude. In addition, the estimated
parameters resulting from the two different routines varied by
less than 15%, and the majority of the parameters varied by
less than 5%. These slight differences can be attributed to
differences in the convergence algorithm.
After determining the model parameters that gave the
best fit to the experimental data, we performed a sensitivity
analysis. Each parameter of the model was varied and the
percent change in exposure (area under the curve [AUC])
to lymphocytes in the plasma, tumor, and lung was
determined.
Results
Lymphocyte Distribution
We first analyzed the lymphocyte distributions before and
after administration of the BFA using the baseline parame-
ters given in Appendices A.1–3. The lymphocyte profiles at
Figure 4. BFA kinetics are determined by the lymphocyte distribution. (A ) BFA clearance curves normalized to injected dose for the various organs. Solid lines
represent the case where lymphocytes are present, and the dotted lines are runs without lymphocytes. Note that the presence of lymphocytes affects the
pharmacokinetics of the BFA, especially in lymphocyte - rich tissue. (B ) BFA clearance curves normalized to the plasma levels. Although there appears to be some
relative accumulation in the tumor, the endogenous trafficking of the lymphocytes still dominates the system.
Figure 3. BFA does not alter the effector cell distribution. Black bars represent
the steady -state effector cell AUC in the various organs before BFA injection.
The dark gray bars are the predicted AUC values after BFA administration.
The parameters associated with these runs are shown in Appendices A.1–3.
In each organ, lymphocyte concentrations varied by less than 1% after
injection, indicating that the BFA is not effective in directing the effector cells to
the tumor under these conditions. The light gray bars show the effect of
increasing the capture site density in the tumor (CV,tumor ) by one order of
magnitude on the AUC. Adjusting this parameter has a significant effect on the
level of lymphocyte exposure in the tumor.
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48 hours after injection of BFA were also analyzed for the
cases where the model parameters were varied from the
baseline values. AUC values for the lymphocyte profiles
were calculated for each organ as a measure of the
cumulative exposure of the tissue to lymphocytes after 48
hours. Figure 3 shows the predicted lymphocyte AUC values
for the baseline case before and after administration of the
BFA (black and dark gray bars, respectively) and for the
case where CV,i in the tumor was increased by one order of
magnitude ( light gray bars). The AUC values are based on
organ concentrations that include the lymphocytes in the
vascular and interstitial space of the organ as well as those
captured or arrested at the vascular endothelium. In general,
the highest level of exposure to lymphocytes is observed in
the tumor, followed by the spleen, lymph node, and skin. The
lowest concentrations are in the liver.
BFA Kinetics
The model predicts a lack of effector cell homing to the
tumor in the baseline case. The model -calculated levels of
BFA in mice are shown in Figure 4, A and B. In each panel
the solid line represents the best - fit level of BFA in each
tissue when lymphocytes are present, and the dotted line
represents the BFA levels in each organ using the same
model parameters but without BFA binding to lymphocytes
( lymphocytes are not present). The plots in Figure 4A show
the amount of BFA in each tissue normalized with respect to
the total dose of BFA. Figure 4B shows the same data except
with the amount of BFA in each tissue normalized to plasma
BFA levels. As a result, the trends in Figure 4B indicate the
rate of elimination from each organ relative to plasma;
increasing values (positive slope) indicate that BFA is
accumulating in the tissue relative to plasma, and de-
creasing values indicate that the BFA is being eliminated
from the tissue at a higher rate than from the plasma. Also
shown in Figure 4B is the experimental data of Bakacs
et al., which compares reasonably well with the model -
calculated data. The model parameters estimated by fitting
the model predictions to experimental data are shown in
Appendix A.3.
Sensitivity Analysis
A sensitivity analysis was performed to assess the effect
of each parameter on the model solution. The information
obtained from this analysis is important in determining
the effect of unknown or estimated parameter values on
the results and in predicting how the system responds to
variations from the baseline case, which can be useful in
optimizing the treatment design. Figure 5 shows the sen-
sitivity of the therapeutic index (TI ) to the model para-
meters. The TI is defined as AUCtumor /AUCplasma where
the AUC represents the cumulative exposure to lympho-
cytes after 48 hours. The sensitivity of TI to changes in the
model parameters was calculated as a percent change
from the baseline case. The effects of increasing and de-
creasing each parameter by an order of magnitude are
shown in Figure 5 as dark and light bars, respectively.
Positive values signify an increase in TI as a result of
the parameter change, and negative values indicate a
decrease. The TI is the most sensitive to the adhesion site
density in the tumor vasculature (CV,i ) followed by the
association and dissociation rate constants for the capture
of the effector cell–BFA complex (K f,i
c and K r,i
c ) and the
association rate constant for the arrest of the complex
(K f,i
a ).
Discussion
The predictions of the model clearly show that physiological
conditions must be carefully considered for successful
BFA-directed effector cell therapy. Figure 3 indicates that
rather than guiding the T cells to the target tissue, the BFA
is being dragged around the system by the cells.
Lymphocyte concentrations in each organ varied by less
than 1% after injection of BFA, indicating that the BFA is not
effective in redirecting the effector cells under these
conditions. Figure 4A shows the specificity of the local-
ization of the BFA, as all data are relative to plasma levels.
Note that compartments with higher baseline concentra-
tions of lymphocytes (e.g., lymph and spleen) show the
largest differences between runs with and without effector
cell–BFA binding. The normalized BFA levels in these
compartments are significantly higher with effector cell–
BFA binding, suggesting that the effector cells are changing
the distribution of the BFA, not vice versa, as was originally
hoped.
Figure 5. Sensitivity of the therapeutic index (TI ) to selected model
parameters. Values represent the percent change compared to the baseline
values for K f,i
CD ( association constant for binding between BFA and CD3);
K r,i
CD (dissociation constant for binding between BFA and CD3); K f,i
ag
( asso-
ciation constant for binding between BFA and antigen ); K r,i
ag
( dissociation
constant for binding between BFA and antigen ); K f,i
c ( association constant for
capture of EC–BFA complex ); K r,i
c ( dissociation constant for capture of EC–
BFA complex ); K f,i
a ( rate constant for arrest of EC–BFA complex ); CD
(number of CD binding sites per cell ); PS (permeability –surface area
product ); Li ( lymph flow out of tumor ); Qi ( blood flow into tumor ); JR,i ( fluid
recirculation flow rate of tumor ). Tumor size; CV,i ( density of capture sites in
the vascular space of tumor ); AEV,i ( density of antigen binding sites in the
extravascular space of tumor ); E kidney
fB ( elimination rate constant for free BFA
in kidney ); Fi ( fraction of EC–BFA complex in extravascular space of tumor
that recirculates ). Dark and light bars correspond to an order of magnitude
increase or decrease in the parameter, respectively. The left - hand panel
shows parameters that affect all organs; those on the right are specific to the
tumor, except for E kidney
fB .
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It is also important to consider the nonnormalized data in
Figure 4B because, in the absence of toxic side effects, it is
the absolute area under these curves that determine
therapeutic benefit. Even larger differences are apparent
here between the runs with and without BFA–effector cell
binding, and the differences are again largest in compart-
ments rich in lymphocytes.
Figure 5 shows the sensitivity of the TI (TI=AUCtumor /
AUCplasma) to changes in various model parameters. The
sensitivity analysis indicates that the greatest positive
impact on the effectiveness of therapy is achieved by
increasing the number of adhesion sites available for
lymphocyte capture in the tumor. Varying the rate constants
for lymphocyte capture and arrest also have a significant
effect on the TI. This implies that selectively modifying
the tumor vasculature by increasing (CV,i ) or by changing
the rate constants in favor of capture and arrest will have
a favorable effect on the therapy. Figure 3 shows that
increasing CV,i by one order of magnitude in the tumor is
capable of increasing the effector cells AUC in the tumor
by more than six times the baseline case. Though these
parameters have the greatest impact on the TI, they may
be difficult to manipulate. Some consideration, therefore,
should be given to other parameters that may be easier
to control. For example, Figure 5 shows that the TI is
also sensitive to the tumor lymph flow rate. Decreasing
this flow rate encourages the accumulation of effector
cells in the tumor; therefore, this parameter should
also be considered in the optimization of this therapy
approach.
Figure 5 also shows that the TI is relatively insensitive to
changes in the BFA. Varying BFA binding to CD3 and to
tumor antigens appear to have little effect on the TI. This
implies that under the model conditions, BFA is not able to
home effector cells to the tumor. Changing the BFA binding
parameters by one order of magnitude is not sufficient to
significantly alter lymphocyte accumulation in the tumor, and
more drastic changes are necessary for successful BFA-
directed effector cell therapy.
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Appendix A
Nomenclature
1. Concentrations
CV,i
fB free BFA in vascular space of compartment i (mol cm3)
CEV,i
fB free BFA in extravascular space of compartment i (mol cm3)
CV,i
bB BFA bound to effector cell (EC) in vascular space of compartment i (mol cm3)
CEV,i
bB BFA bound to EC extravascular space of compartment i (mol cm3)
CV,i
EB EC–BFA complex in vascular space of compartment i (mol cm3)
CEV,i
EB EC–BFA complex in extravascular space of compartment i (mol cm3)
CV,i
agB
BFA bound to antigen in vascular space of compartment i (mol cm3 )
CEV,i
agB
BFA bound to antigen in extravascular space of compartment i (mol cm3)
CV,i
cEB captured EC–BFA complex in vascular space of compartment i (mol cm3)
CV,i
aEB arrested EC–BFA complex in vascular space of compartment i (mol cm3)
CV,i
agEB EC–BFA complex bound to antigen in vascular space of compartment i (mol cm3)
CEV,i
agEB lymphocyte–BFA complex bound to antigen in extravascular space of compartment i (mol cm3)
CEV,i
nB nonspecifically bound BFA in vascular space of compartment i (mol cm3)
CEV,i
nEB nonspecifically bound EC–BFA complex in extravascular space of compartment i (mol cm3)
CV,i
total total concentration of cells in vascular space of compartment i (mol cm3)
CEV,i
total total concentration of cells in extravascular space of compartment i (mol cm3 )
2. Kinetic Parameters
Kf,i
CD association constant for binding between BFA and CD3 on EC in compartment i (cm3 mol1 min1)
Kr,i
CD dissociation constant for binding between BFA and CD3 on EC in compartment i (min1)
Kf,i
ag
association constant for binding between BFA and antigen in compartment i (cm3 mol1 min1)
Kr,i
ag
dissociation constant for binding between BFA and antigen in compartment i (min1 )
Kf,i
c association constant for capture of EC–BFA complex in compartment i (cm3 mol1 min1 )
Kr,i
c dissociation constant for capture of EC–BFA complex in compartment i (min1)
Kf,i
a rate constant for arrest of EC–BFA complex in compartment i (min1 )
Kf,i
n association constant for nonspecific binding of BFA in compartment i (min1)
Kr,i
n dissociation constant for nonspecific binding of BFA in compartment i (min1)
Ekidney
fB elimination rate constant for free BFA in kidney (cm3 min1 )
Ei
cEB elimination rate constant for captured EC–BFA complex in compartment i (min1)
Ei
aEB elimination rate constant for arrested EC–BFA complex in compartment i (min1)
J i
aEB transmigration rate constant for arrested EC–BFA complex in compartment i (min1)
J i
fB transcapillary exchange rate of free BFA in compartment i (mol min1)
JS,i transcapillary fluid flow rate through small pores in compartment i (cm
3 min1 )
JL,i transcapillary fluid flow rate through large pores in compartment i (cm
3 min1 )
JR,i fluid recirculation flow rate of compartment i (cm
3 min1)
P baseline production rate of EC in plasma (mol min1 )
3. Flow Rates
Qi blood flow into compartment i (cm
3 min1 )
L i lymph flow out of compartment i (cm
3 min1)
Qhepatic blood flow into liver before the addition of blood flow from GI and spleen (cm
3 min1)
4. Volumes
VV,i vascular volume of compartment i (cm
3)
VEV,i extravascular volume of compartment i (cm
3)
5. Other Parameters
Fi fraction of EC–BFA complex in extravascular space of compartment i that recirculates
CD number of CD binding sites per cell (mol mol1)
AV,i density of antigen binding sites in the vascular space of compartment i (mol cm
3)
AEV,i density of antigen binding sites in the extravascular space of compartment i (mol cm
3)
CV,i density of capture sites in the vascular space of compartment i (mol cm
3)
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Appendix B
Mass Balance Equations
1. Plasma
1.1 Free BFA
VV;plasma
dC fB
V;plasma
dt ¼ ðQlungLlungÞC fBV;lung

 Qhepatic þQlnode þQtumor þQbone þQGI
þQheart þQkidney þQmuscle þQskin þQspleen
!
C fBV;plasma
KCDf ;plasmaC fBV;plasmafCDV;plasmaVV;plasma
þKCDr ;plasmaCbBV;plasmaVV;plasma
1.2 Free BFA–effector cell complex
VV;plasma
dCEB
V;plasma
dt ¼ ðQlungLlungÞCEBV;lung

 Qhepatic þQlnode þQtumor þQbone þQGI
þQheart þQkidney þQmuscle þQskin þQspleen
!
CEBV;plasma
þP
1.3 BFA bound to effector cells
VV;plasma
dCbB
V;plasma
dt ¼ ðQlungLlungÞCEBV;lungCbBV;lung

C totalV;lung

 Qhepatic þQlnode þQtumor þQbone þQGI
þQheart þQkidney þQmuscle þQskin þQspleen
!
CbBV;plasma
þKCDf ;plasmaC fBV;plasmafCDV;plasmaVV;plasma
KCDr ;plasmaCbBV;plasmaVV;plasma
2. Liver
2.1 Free BFA in vascular space
VV;liver
dC fB
V;liver
dt ¼ QhepaticC fBV;plasma
þðQspleenLspleenÞC fBV;spleen
þðQGILGIÞC fBV;GI
ðQliverLliverÞC fBV;liver
J fBliver
KCDf ;liverC fBV;liverfCDV;liverVV;liver
þKCDr ;liverCbBV;liverVV;liver
2.2 Free EC–BFA complex in vascular space
VV;liver
dCEB
V;liver
dt
¼ QhepaticCEBV;plasma
þðQspleenLspleenÞCEBV;spleen
þðQGILGIÞCEBV;GI
ðQliverLliverÞCEBV;liver
K cf ;liverCEBV;liverfC fBV;liverVV;liver
þK cr ;liverCcEBV;liverVV;liver
2.3 Captured EC–BFA complex in vascular space
VV;liver
dCcEB
V;liver
dt ¼ K cf ;liverCEBV;liverfCV;liverVV;liver
K cr ;liverCcEBV;liverVV;liver
K af ;liverCcEBV;liverVV;liver
E cEBliverCcEBV;liverVV;liver
2.4 Arrested EC–BFA complex in vascular space
VV;liver
dCaEB
V;liver
dt ¼ K af ;liverCcEBV;liverVV;liver
EaEBliverCaEBV;liverVV;liver
JaEBliverCaEBV;liverVV;liver
2.5 BFA bound to effector cells in vascular space
VV;liver
dCbB
V;liver
dt ¼ QhepaticCbBV;plasma
þðQspleenLspleenÞCbBV;spleenCEBV;spleen=C totalV;spleen
þðQGILGIÞCbBV;liverCEBV;GI=C totalV;GI
fCDV,i density of free CD3 sites in the vascular space of compartment i (mol cm
3 )
fCDEV,i density of free CD3 sites in the extravascular space of compartment i (mol cm
3)
oCDV,i density of occupied CD3 sites in the vascular space of compartment i (mol cm
3)
oCDEV,i density of occupied CD3 sites in the extravascular space of compartment i (mol cm
3)
fCV,i density of free capture sites in the vascular space of compartment i (mol cm
3)
fAV,i density of free antigen sites in the vascular space of compartment i (mol cm
3)
fAEV,i density of free antigen sites in the extravascular space of compartment i (mol cm
3)
PeS,i Pecle`t number for flow through small pores in compartment i
PeL,i Pecle`t number for flow through large pores in compartment i
k i partition coefficient for free BFA between vascular and extra vascular space in compartment i
PS permeability–surface area product (cm3 min1 g1)
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ðQliverLliverÞCbBV;liverCEBV;liver=C totalV;liver
þKCDf ;liverC fBV;liverfCDV;liverVV;liver
KCDr ;liverCbBV;liverVV;liver
JaEBliverCaEBV;liverCbBV;liverVV;liver=C totalV;liver
E cEBliverCcEBV;liverCbBV;liverVV;liver=C totalV;liver
EaEBliverCaEBV;liverCbBV;liverVV;liver=C totalV;liver
2.6 Free BFA in the extravascular space
VEV;liver
dC fB
EV;liver
dt
¼ J fBliver
LliverC fBEV;liver
KCDf ;liverC fBEV;liverfCDEV;liverVEV;liver
þKCDr ;liverðCbBEV;liverCnEBEV;liverÞVEV;liver
K nf ;liverC fBEV;liverVEV;liver
þK nr ;liverCnBEV;liverVEV;liver
2.7 Nonspecifically bound BFA in the extravascular space
VEV;liver
dCnB
EV;liver
dt ¼ K nf ;liverC fBEV;liverVEV;liver
K nr ;liverCnBEV;liverVEV;liver
KCDf ;liverCnBEV;liverCEBEV;liverfCDEV;liverVEV;liver=C totalEV;liver
þKCDr ;liverCnEBEV;liverVEV;liver
2.8 Free EC–BFA complex in the extravascular space
VEV;liver
dCEB
EV;liver
dt ¼ JaEBliverCaEBV;liverVV;liver
þK nr ;liverCnEBEV;liverVEV;liver
K nf ;liverCEBEV;liveroCDEV;liverVEV;liver=C totalEV;liver
LliverCEBEV;liverFliver
KCDf ;liverCnBEV;liverCEBEV;liverfCDEV;liverVEV;liver=C totalEV;liver
þKCDr ;liverCnEBEV;liverVEV;liver
2.9 Nonspecifically bound EC–BFA complex in the
extravascular space
VEV;liver
dCnEB
EV;liver
dt ¼ K nf ;liverCEBEV;liveroCDEV;liverVEV;liver=C totalEV;liver
K nr ;liverCnEBEV;liverVEV;liver
þKCDf ;liverCnBEV;liverCEBEV;liverfCDEV;liverVEV;liver=C totalEV;liver
KCDr ;liverCnEBEV;liverVEV;liver
2.10 BFA bound to effector cells in the extravascular space
VEV;liver
dCbB
EV;liver
dt ¼ KCDf ;liverC fBEV;liverfCDEV;liverVEV;liver
KCDr ;liverðCbBEV;liverCnEBEV;liverÞVEV;liver
þKCDf ;liverCnBEV;liverCEBEV;liverfCDEV;liverVEV;liver=C totalEV;liver
KCDr ;liverCnEBEV;liverVEV;liver
þJaEBliverCaEBV;liverCbBV;liverVV;liver=C totalV;liver
LliverCEBEV;liverFV;liverCbBEV;liver=C totalEV;liver
3. Lung
3.1 Free BFA in vascular space
VV;lung
dC fB
V;lung
dt ¼ ðQliverLliverÞC fBV;liver
þðQkidneyLkidneyÞC fBV;kidney
þðQtumorLtumorÞC fBV;tumor
þðQskinLskinÞC fBV;skin
þðQmuscleLmuscleÞC fBV;muscle
þðQboneLboneÞC fBV;bone
þðQheartLheartÞC fBV;heart
þQlnodeC fBV;lnode
þLlnodeC fBEV;lnode
ðQlungLlungÞC fBV;lung
J fBlnode
KCDf ;lungC fBV;lungfCDV;lungVV;lung
þKCDr ;lungCbBV;lungVV;lung
3.2 Free EC–BFA complex in vascular space
VV;lung
dCEB
V;liver
dt ¼ ðQliverLliverÞCEBV;liver
þðQkidneyLkidneyÞCEBV;kidney
þðQtumorLtumorÞCEBV;tumor
þðQskinLskinÞCEBV;skin
þðQmuscleLmuscleÞCEBV;muscle
þðQboneLboneÞCEBV;bone
þðQheartLheartÞCEBV;heart
þQlnodeCEBV;lnode
þLlnodeCEBEV;lnodeFlnode
ðQlungLlungÞCEBV;lung
K cf ;liverCEBV;liverfCV;liverVV;lung
þK cr ;liverCcEBV;liverVV;lung
3.3 Captured EC–BFA complex in vascular space
VV;lung
dCcEB
V;liver
dt ¼ Kcf ;lungCEBV;lungfCV;lungVV;lung
K cr ;lungCcEBV;lungVV;lung
K af ;lungCcEBV;lungVV;lung
EcEBlungCcEBV;lungVV;lung
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3.4 Arrested EC–BFA complex in vascular space
VV;lung
dCaEB
V;liver
dt ¼ K af ;lungCcEBV;lungVV;lung
EaEBlungCaEBV;lungVV;lung
JaEBlungCaEBV;lungVV;lung
3.5 BFA bound to effector cells in vascular space
VV;lung
dCbB
V;liver
dt ¼ ðQliverLliverÞCbBV;liverCEBV;liver=C totalV;liver
þðQkidneyLkidneyÞCbBV;kidneyCEBV;kidney=C totalV;kidney
þðQtumorLtumorÞCbBV;tumorCEBV;tumor=C totalV;tumor
þðQskinLskinÞCbBV;skinCEBV;skin=C totalV;skin
þðQmuscleLmuscleÞCbBV;muscleCEBV;muscle=C totalV;muscle
þðQboneLboneÞCbBV;boneCEBV;bone=C totalV;bone
þðQheartLheartÞCbBV;heartCEBV;heart=C totalV;heart
þQlnodeCbBV;lnodeCEBV;lnode=C totalV;lnode
þLlnodeCbBEV;lnodeCEBEV;lnodeFlnode=C totalEV;lnode
ðQlungLlungÞCbBV;lungCEBV;lung=C totalV;lung
þKCDf ;lungC fBV;lungfCDV;lungVV;lung
KCDr ;lungCbBV;lungVV;lung
JaEBlungCaEBV;lungCbBV;lungVV;lung=C totalV;lung
E cEBlungCcEBV;lungCbBV;lungVV;lung=C totalV;lung
EaEBlungCaEBV;lungCbBV;lungVV;lung=C totalV;lung
3.6 Free BFA in the extravascular space
VEV;lung
dC fB
EV;lung
dt ¼ J fBlung
LlungC fBEV;lung
KCDf ;lungC fBEV;lungfCDEV;lungVEV;lung
þKCDr ;lungðCbBEV;lungCnEBEV;lungÞVEV;lung
K nf ;lungC fBEV;lungVEV;lung
þK nr ;lungCnBEV;lungVEV;lung
3.7 Nonspecifically bound BFA in the extravascular space
VEV;lung
dCnB
EV;lung
dt ¼ K nf ;lungC fBEV;lungVEV;lung
K nr ;lungCnBEV;lungVEV;lung
KCDf ;lungCnBEV;lungCEBEV;lungfCDEV;lungVEV;lung=C totalEV;lung
þKCDr ;lungCnEBEV;lungVEV;lung
3.8 Free EC–BFA complex in the extravascular space
VEV;lung
dCEB
EV;lung
dt ¼ JaEBlungCaEBV;lungVV;lung
þK nr ;lungCnEBEV;lungVEV;lung
K nf ;lungCEBEV;lungoCDEV;lungVEV;lung=C totalEV;lung
LlungCEBEV;lungFlung
KCDf ;lungCnBEV;lungCEBEV;lungfCDEV;lungVEV;lung=C totalEV;lung
þKCDr ;lungCnEBEV;lungVEV;lung
3.9 Nonspecifically bound EC–BFA complex in the
extravascular space
VEV;lung
dCnEB
EV;lung
dt ¼ K nf ;lungCEBEV;lungoCDEV;lungVEV;lung=C totalEV;lung
K nr ;lungCnEBEV;lungVEV;lung
þKCDf ;lungCnBEV;lungCEBEV;lungfCDEV;lungVEV;lung=C totalEV;lung
KCDr ;lungCnEBEV;lungVEV;lung
3.10 BFA bound to effector cells in the extravascular space
VEV;lung
dCbB
EV;lung
dt ¼ KCDf ;lungC fBEV;lungfCDEV;lungVEV;lung
KCDr ;lungðCbBEV;lungCnEBEV;lungÞVEV;lung
þKCDf ;lungCnBEV;lungCEBEV;lungfCDEV;lungVEV;lung=C totalEV;lung
KCDr ;lungCnEBEV;lungVEV;lung
þJaEBlungCaEBV;lungCbBV;lungVV;lung=C totalV;lung
LlungCEBEV;lungFlungCbBEV;lung=C totalEV;lung
4. Lymph Node
4.1 Free BFA in vascular space
VV;lnode
dC fB
V;lnode
dt ¼ QlnodeC fBV;plasma
QlnodeC fBV;lnode
J fBlnode
KCDf ;lnodeC fBV;lnodefCDV;lnodeVV;lnode
þKCDr ;lnodeCbBV;lnodeVV;lnode
4.2 Free EC–BFA complex in vascular space
VV;lnode
dCEB
V;lnode
dt ¼ QlnodeCEBV;plasma
QlnodeCEBV;lnode
K cf ;lnodeCEBV;lnodefCV;lnodeVV;lnode
þK cr ;lnodeCcEBV;lnodeVV;lnode
4.3 Captured EC–BFA complex in vascular space
VV;lnode
dCcEB
V;lnode
dt ¼ K cf ;lnodeCEBV;lnodefCV;lnodeVV;lnode
K cr ;lnodeCcEBV;lnodeVV;lnode
K af ;lnodeCcEBV;lnodeVV;lnode
E cEBlnodeCcEBV;lnodeVV;lnode
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4.4 Arrested EC–BFA complex in vascular space
VV;lnode
dCaEB
V;lnode
dt ¼ K af ;lnodeCcEBV;lnodeVV;lnode
EaEBlnodeCaEBV;lnodeVV;lnode
JaEBlnodeCaEBV;lnodeVV;lnode
4.5 BFA bound to effector cells in vascular space
VV;lnode
dCbB
V;lnode
dt ¼ QlnodeCbBV;plasma
QlnodeCbBV;lnodeCEBV;lnode=C totalV;lnode
þKCDf ;lnodeC fBV;lnodefCDV;lnodeVV;lnode
KCDr ;lnodeCbBV;lnodeVV;lnode
JaEBlnodeCaEBV;lnodeCbBV;lnodeVV;lnode=C totalV;lnode
EcEBlnodeCcEBV;lnodeCbBV;lnodeVV;lnode=C totalV;lnode
EaEBlnodeCaEBV;lnodeCbBV;lnodeVV;lnode=C totalV;lnode
4.6 Free BFA in the extravascular space
VEV;lnode
dC fB
EV;lnode
dt ¼ J fBlnode
þLlungC fBEV;lung
þLGIC fBEV;GI
þLliverC fBEV;liver
þLspleenC fBEV;spleen
þLheartC fBEV;heart
þLkidneyC fBEV;kidney
þLskinC fBEV;skin
þLmuscleC fBEV;muscle
þLboneC fBEV;bone
þLtumorC fBEV;tumor
LlnodeC fBEV;lnode
KCDf ;lnodeC fBEV;lnodefCDEV;lnodeVEV;lnode
þKCDr ;lnodeðCbBEV;lnodeCnEBEV;lnodeÞVEV;lnode
K nf ;lnodeC fBEV;lnodeVEV;lnode
þK nr ;lnodeCnBEV;lnodeVEV;lnode
4.7 Nonspecifically bound BFA in the extravascular space
VEV;lnode
dCnB
EV;lnode
dt ¼ K nf ;lnodeC fBEV;lnodeVEV;lnode
K nr ;lnodeCnBEV;lnodeVEV;lnode
KCDf ;lnodeCnBEV;lnodeCEBEV;lnodefCDEV;lnodeVEV;lnode=C totalEV;lnode
þKCDr ;lnodeCnEBEV;lnodeVEV;lnode
4.8 Free EC–BFA complex in the extravascular space
VEV;lnode
dCEB
EV;lnode
dt ¼ LlungCEBEV;lungFlung
þLGICEBEV;GIFGI
þLliverCEBEV;liverFliver
þLspleenCEBEV;spleenFspleen
þLheartCEBEV;heartFheart
þLkidneyCEBEV;kidneyFkidney
þLskinCEBEV;skinFskin
þLmuscleCEBEV;muscleFmuscle
þLboneCEBEV;boneFbone
þLtumorCEBEV;tumorFtumor
LlnodeCEBEV;lnodeFlnode
þJaEBlnodeCaEBV;lnodeVV;lnode
þK nr ;lnodeCnEBEV;lnodeVEV;lnode
K nf ;lnodeCEBEV;lnodeoCDEV;lnodeVEV;lnode=C totalEV;lnode
KCDf ;lnodeCnBEV;lnodeCEBEV;lnodefCDEV;lnodeVEV;lnode=C totalEV;lnode
þKCDr ;lnodeCnEBEV;lnodeVEV;lnode
4.9 Nonspecifically bound EC–BFA complex in the
extravascular space
VEV;lnode
dCnEB
EV;lnode
dt ¼ K nf ;lnodeCEBEV;lnodeoCDEV;lnodeVEV;lnode=C totalEV;lnode
K nr ;lnodeCnEBEV;lnodeVEV;lnode
þKCDf ;lnodeCnBEV;lnodeCEBEV;lnodefCDEV;lnodeVEV;lnode=C totalEV;lnode
KCDr ;lnodeCnEBEV;lnodeVEV;lnode
4.10 BFA bound to effector cells in the extravascular space
VEV;lnode
dCbB
EV;lnode
dt ¼ LlungCEBEV;lungFlungCbBEV;lung=C totalEV;lung
þLGICEBEV;GIFGICbBEV;GI=C totalEV;GI
þLliverCEBEV;liverFliverCbBEV;liver=C totalEV;liver
þLspleenCEBEV;spleenFspleenCbBEV;spleen=C totalEV;spleen
þLheartCEBEV;heartFheartCbBEV;heart=C totalEV;heart
þLkidneyCEBEV;kidneyFkidneyCbBEV;kidney=C totalEV;kidney
þLskinCEBEV;skinFskinCbBEV;skin=C totalEV;skin
þLmuscleCEBEV;muscleFmuscleCbBEV;muscle=C totalEV;muscle
þLboneCEBEV;boneFboneCbBEV;bone=C totalEV;bone
þLtumorCEBEV;tumorFtumorCbBEV;tumor=C totalEV;tumor
þKCDf ;lnodeC fBEV;lnodefCDEV;lnodeVEV;lnode
KCDr ;lnodeðCbBEV;lnodeCnEBEV;lnodeÞVEV;lnode
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þKCDf ;lnodeCnBEV;lnodeCEBEV;lnodefCDEV;lnodeVEV;lnode=C totalEV;lnode
KCDr ;lnodeCnEBEV;lnodeVEV;lnode
þJaEBlnodeCaEBV;lnodeCbBV;lnodeVV;lnode=C totalV;lnode
LlnodeCEBEV;lnodeFlnodeCbBEV;lnode=C totalEV;lnode
5. Tumor
5.1 Free BFA in vascular space
VV;tumor
dC fB
V;tumor
dt ¼ QtumorC fBV;plasma
ðQtumorLtumorÞC fBV;tumor
J fBtumor
KCDf ;tumorC fBV;tumorfCDV;tumorVV;tumor
þKCDr ;tumorðCbBV;tumorCagEBV;tumorÞVV;tumor
K agf ;tumorC fBV;tumorfAV;tumorVV;tumor
þK agr ;tumorCagBV;tumorVV;tumor
5.2 BFA bound to vascular antigens in vascular space
VV;tumor
dC
agB
V;tumor
dt ¼ K agf ;tumorC fBV;tumorfAV;tumorVV;tumor
K agr ;tumorCagBV;tumorVV;tumor
KCDf ;tumorCagBV;tumorCEBV;tumorfCDV;tumorVV;tumor=C totalV;tumor
þKCDr ;tumorCagEBV;tumorVV;tumor
5.3 Free EC–BFA complex in vascular space
VV;tumor
dCEB
V;tumor
dt ¼ QtumorCEBV;plasma
ðQtumorLtumorÞCEBV;tumor
K cf ;tumorCEBV;tumorfCV;tumorVV;tumor
þK cr ;tumorCcEBV;tumorVV;tumor
K agf ;tumorCEBV;tumorfAV;tumoroCDV;tumorVV;tumor=C totalV;tumor
þK agr ;tumorCagEBV;tumorVV;tumor
KCDf ;tumorCagBV;tumorCEBV;tumorfCDV;tumorVV;tumor=C totalV;tumor
þKCDr ;tumorCagEBV;tumorVV;tumor
5.4 Normal captured EC–BFA complex in vascular space
VV;tumor
dCEB
V;tumor
dt ¼ K cf ;tumorCEBV;tumorfCV;tumorVV;tumor
K cr ;tumorCcEBV;tumorVV;tumor
K af ;tumorCcEBV;tumorVV;tumor
E cEBtumorCcEBV;tumorVV;tumor
5.5 Enhanced captured EC–BFA complex in vascular space
VV;tumor
dCagEB
V;tumor
dt ¼ K agf ;tumorCEBV;tumorfAV;tumoroCDV;tumorVV;tumor=C totalV;tumor
K agr ;tumorCagEBV;tumorVV;tumor
K af ;tumorCagEBV;tumorVV;tumor
EcEBtumorCagEBV;tumorVV;tumor
þKCDf ;tumorCagBV;tumorCEBV;tumorfCDV;tumorVV;tumor=C totalV;tumor
KCDr ;tumorCagEBV;tumorVV;tumor
5.6 Arrested EC–BFA complex in vascular space
VV;tumor
dCaEB
V;tumor
dt ¼ K af ;tumorCcEBV;tumorVV;tumor
þK af ;tumorCagEBV;tumorVV;tumor
EaEBtumorCaEBV;tumorVV;tumor
JaEBtumorCaEBV;tumorVV;tumor
5.7 BFA bound to effector cells in vascular space
VV;tumor
dCbB
V;tumor
dt ¼ QtumorCbBV;tumor
ðQtumorLtumorÞCbBV;tumorCEBV;tumor=C totalV;tumor
þKCDf ;tumorC fBV;tumorfCDV;tumorVV;tumor
KCDr ;tumorðCbBV;tumorCagEBV;tumorÞVV;tumor
þKCDf ;tumorCagBV;tumorCEBV;tumorfCDV;tumorVV;tumor=C totalV;tumor
KCDr ;tumorCagEBV;tumorVV;tumor
JaEBtumorCaEBV;tumorCbBV;tumorVV;tumor=C totalV;tumor
E cEBtumorCcEBV;tumorCbBV;tumorVV;tumor=C totalV;tumor
E cEBtumorCagEBV;tumorCbBV;tumorVV;tumor=C totalV;tumor
EaEBtumorCaEBV;tumorCbBV;tumorVV;tumor=C totalV;tumor
5.8 Free BFA in the extravascular space
VEV;tumor
dC fB
EV;tumor
dt ¼ J fBtumor
LtumorC fBEV;tumor
KCDf ;tumorC fBEV;tumorfCDEV;tumorVEV;tumor
þKCDr ;tumorðCbBEV;tumorCnEBEV;tumorCagEBEV;tumorÞVEV;tumor
K agf ;tumorC fBEV;tumorfAEV;tumorVEV;tumor
þK agr ;tumorCagBEV;tumorVEV;tumor
K nr ;tumorC fBEV;tumorVEV;tumor
þK nr ;tumorCnBEV;tumorVEV;tumor
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5.9 BFA bound to tumor antigens in the extravascular space
VEV;tumor
dC
agB
EV;tumor
dt ¼ K agf ;tumorC fBEV;tumorfAEV;tumorVEV;tumor
K agr ;tumorCagBEV;tumorVEV;tumor
KCDf ;tumorCagBEV;tumorCEBEV;tumorfCDEV;tumorVEV;tumor=C totalEV;tumor
þKCDr ;tumorCagEBEV;tumorVEV;tumor
5.10 Nonspecifically bound BFA in the extravascular space
VEV;tumor
dCnB
EV;tumor
dt ¼ K nf ;tumorC fBEV;tumorVEV;tumor
K nr ;tumorCnBEV;tumorVEV;tumor
KCDf ;tumorCnBEV;tumorCEBEV;tumorfCDEV;tumorVEV;tumor=C totalEV;tumor
þKCDr ;tumorCnEBEV;tumorVEV;tumor
5.11 Free EC–BFA complex in the extravascular space
VEV;tumor
dCEB
EV;tumor
dt ¼ JaEBtumorCaEBV;tumorVV;tumor
K agf ;tumorCEBEV;tumorfAEV;tumoroCDEV;tumorVEV;tumor=C totalEV;tumor
þK agr ;tumorCagEBEV;tumorVEV;tumor
K nf ;tumorCEBEV;tumoroCDEV;tumorVEV;tumor=C totalEV;tumor
þK nr ;tumorCnEBEV;tumorVEV;tumor
LtumorCEBEV;tumorFtumor
KCDf ;tumorCagBEV;tumorCEBEV;tumorfCDEV;tumorVEV;tumor=C totalEV;tumor
KCDf ;tumorCnBEV;tumorCEBEV;tumorfCDEV;tumorVEV;tumor=C totalEV;tumor
þKCDr ;tumorCagEBEV;tumorVEV;tumor
þKCDr ;tumorCnEBEV;tumorVEV;tumor
5.12 Nonspecifically bound EC–BFA complex in the
extravascular space
VEV;tumor
dCnEB
EV;tumor
dt ¼ K nf ;tumorCEBEV;tumoroCDEV;tumorVEV;tumor=C totalEV;tumor
K nr ;tumorCnEBEV;tumorVEV;tumor
þKCDf ;tumorCnBEV;tumorCEBEV;tumorfCDEV;tumorVEV;tumor=C totalEV;tumor
KCDr ;tumorCnEBEV;tumorVEV;tumor
5.13 EC–BFA bound to tumor antigens in the extravascular
space
VEV;tumor
dC
agEB
EV;tumor
dt ¼ K agf ;tumorCEBEV;tumorfAEV;tumoroCDEV;tumorVEV;tumor=C totalEV;tumor
K agr ;tumorCagEBEV;tumorVEV;tumor
þKCDf ;tumorCagBEV;tumorCEBEV;tumorfCDEV;tumorVEV;tumor=C totalEV;tumor
KCDr ;tumorCagEBEV;tumorVEV;tumor
5.14 BFA bound to effector cells in the extravascular space
VEV;tumor
dCbB
EV;tumor
dt ¼ KCDf ;tumorC fBEV;tumorfCDEV;tumorVEV;tumor
KCDr ;tumorðCbBEV;tumorCagEbEV;tumorCnEBEV;tumorÞVEV;tumor
þKCDf ;tumorCagBEV;tumorCEBEV;tumorfCDEV;tumorVEV;tumor=C totalEV;tumor
KCDr ;tumorCagEBEV;tumorVEV;tumor
þKCDf ;tumorCnBEV;tumorCEBEV;tumorfCDEV;tumorVEV;tumor=C totalEV;tumor
KCDr ;tumorCnEBEV;tumorVEV;tumor
þJaEBtumorCaEBV;tumorCbBV;tumorVV;tumor=C totalV;tumor
LtumorCEBEV;tumorFtumorCbBEV;tumor=C totalEV;tumor
6. Other Organs (Bone, GI, Heart, Kidney, Muscle, Skin,
and Spleen)
6.1.a Free BFA in vascular space (bone, GI, heart, muscle,
skin, and spleen)
VV;i
dC fB
V;i
dt ¼ QiC fBV;plasma
ðQiLi ÞC fBV;i
J fBi
KCDf ;i C fBV;i fCDV;iVV;i
þKCDr ;i CbBV;i VV;i
6.1.b Free BFA in vascular space (kidney)
VV;kidney
dC fB
V;kidney
dt ¼ QkidneyC fBV;plasma
ðQkidneyLkidneyÞC fBV;kidney
J fBkidney
KCDf ;kidneyC fBV;kidneyfCDV;kidneyVV;kidney
þKCDr ;kidneyCbBV;kidneyVV;kidney
E fBkidneyCbBV;kidney
6.2 Free EC–BFA complex in vascular space
VV;i
dCEB
V;i
dt ¼ QiCEBV;plasma
ðQiLi ÞCEBV;i
K cf ;iCEBV;i fCV;iVV;i
þK cr ;iCcEBV;i VV;i
6.3 Captured EC–BFA complex in vascular space
VV;i
dCcEB
V;i
dt ¼ K cf ;iCEBV;i fCV;iVV;i
K cr ;iCcEBV;i VV;i
K af ;iCcEBV;i VV;i
EcEBi CcEBV;i VV;i
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6.4 Arrested EC–BFA complex in vascular space
VV;i
dCaEB
V;i
dt ¼ K af ;iCcEBV;i VV;i
EaEBi CaEBV;i VV;i
JaEBi CaEBV;i VV;i
6.5 BFA bound to effector cells in vascular space
VV;i
dCbB
V;i
dt ¼ QiCbBV;plasma
ðQiLi ÞCbBV;i CEBV;i =C totalV;i
þKCDf ;i C fBV;i fCDV;iVV;i
KCDr ;i CbBV;i VV;i
JaEBi CaEBV;i CbBV;i VV;i=C totalV;i
EcEBi CcEBV;i CbBV;i VV;i=C totalV;i
EaEBi CaEBV;i CbBV;i VV;i=C totalV;i
6.6 Free BFA in the extravascular space
VEV;i
dC fB
EV;i
dt ¼ J fBi
LiC fBEV;i
KCDf ;i C fBEV;i fCDEV;iVEV;i
þKCDr ;i ðCbBEV;iCnEBEV;i ÞVEV;i
K nf ;iC fBEV;iVEV;i
þK nr ;iCnBEV;iVEV;i
6.7 Nonspecifically bound BFA in the extravascular space
VEV;i
dCnB
EV;i
dt ¼ K nf ;iC fBEV;iVEV;i
K nr ;iCnBEV;iVEV;i
KCDf ;i CnBEV;iCEBEV;i fCDEV;iVEV;i=C totalEV;i
þKCDr ;i CnEBEV;i VEV;i
6.8 Free EC–BFA complex in the extravascular space
VEV;i
dCEB
EV;i
dt ¼ JaEBi CaEBV;i VV;i
þK nr ;iCnEBEV;i VEV;i
K nf ;iCEBEV;i oCDEV;iVEV;i=C totalEV;i
LiCEBEV;i Fi
KCDf ;i CnBEV;iCEBEV;i fCDEV;iVEV;i=C totalEV;i
þKCDr ;i CnEBEV;i VEV;i
6.9 Nonspecifically bound EC–BFA complex in the
extravascular space
VEV;i
dCnEB
EV;i
dt ¼ K nf ;iCEBEV;i oCDEV;iVEV;i=C totalEV;i
K nr ;iCnEBEV;i VEV;i
þKCDf ;i CnBEV;iCEBEV;i fCDEV;iVEV;i=C totalEV;i
KCDr ;i CnEBEV;i VEV;i
6.10 BFA bound to effector cells in the extravascular space
VEV;i
dCbB
EV;i
dt ¼ KCDf ;i C fBEV;i fCDEV;iVEV;i
KCDr ;i ðCbBEV;iCnEBEV;i ÞVEV;i
þKCDf ;i CnBEV;iCEBEV;i fCDEV;i VEV;i=C totalEV;i
KCDr ;i CnEBEV;i VEV;i
þJaEBi CaEBV;i CbBV;i VV;i=C totalV;i
LiCEBEV;i FiCbBEV;i=C totalEV;i
Appendix C
Other Model Equations
1. Plasma
1.1 Adhesion site density
fCDV;plasma ¼ CEBV;plasmaCDCbBV;plasma
2. Tumor
2.1 Transcapillary exchange rate of free BFA
J fBtumor ¼ JL;tumorð1L;tumorÞCfBV;tumor
þPSL;tumor½C fBV;tumorðC fBEV;tumor=ktumorÞPeL;tumor=ðePeL;tumor1Þ
þJS;tumorð1S;tumorÞC fBV;tumor
þPSS;tumor½C fBV;tumorðC fBEV;tumor=ktumorÞPeS;tumor=ðePeS;tumor1Þ
2.2 Total concentration of cells
C totalV;tumor ¼ CEBV;tumor þ CagEBV;tumor þ CcEBV;tumor þ CaEBV;tumor
C totalEV;tumor ¼ CEBEV;tumor þ CagEBEV;tumor þ CnEBEV;tumor
2.3 Adhesion site densities
fCDV;tumor ¼ C totalV;tumorCDCbBV;tumor
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fCDEV;tumor ¼ C totalEV;tumorCDCbBEV;tumor
oCDV;tumor ¼ CbBV;tumor
oCDEV;tumor ¼ CbBEV;tumor
fAV;tumor ¼ AV;tumorCagEBV;tumorCagBV;tumor
fAEV ;tumor ¼ AEV ;tumorCagEBEV ;tumorCagBEV ;tumor
fCV ;tumor ¼ CtumorCcEBV ;tumorCaEBV ;tumor
3. Other Organs (Lung, Liver, Lymph Node, Bone, GI,
Heart, Kidney, Muscle, Skin, and Spleen)
3.1 Transcapillary exchange rate of free BFA
J fBi ¼ JL;i ð1L;i ÞC fBV;i
þPSL;i ½C fBV;iðC fBEV;i=ki ÞPeL;i=ðePeL;i1Þ
þJS;i ð1S;i ÞC fBV;i
þPSS;i ½C fBV;iðC fBEV;i=ki ÞPeS;i=ðePeS;i1Þ
3.2 Total concentration of cells
C totalV;i ¼ CEBV;i þ CcEBV;i þ CaEBV;i
C totalEV;i ¼ CEBEV;i þ CnEBEV;i
3.3 Adhesion site densities
fCDV;i ¼ C totalV;i CDCbBV;i
fCDEV;i ¼ C totalEV;i CDCbBEV;i
oCDV;i ¼ CbBV;i
oCDEV;i ¼ CbBEV;i
fCV;i ¼ CiCcEBV;i CaEBV;i
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